Loading the records…
Loading the records…
H.R. 6994 (Mental Health TALK SAFE Act) is an early-stage bill that would permanently expand telehealth prescribing of controlled substances for mental health and opioid use disorder. It is referred to committee with one sponsor and one cosponsor — a low-momentum legislative path. No market-moving implications until committee markup and floor consideration. Telehealth stocks $TDOC and $AMWL have already seen 30-day gains of +4.77% and +17.11%, respectively, reflecting the existing regulatory tailwind (DEA rulemaking) that this bill seeks to codify.
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
No near-term market implications. This bill is purely procedural at its current stage. Investors with exposure to telehealth stocks ($TDOC at $5.71, $AMWL at $6.16) should monitor committee action and DEA final rulemaking for the regulatory catalyst. The bill's passage would structurally expand the TAM for both companies, but the probability of enactment in the 119th Congress is low without broader cosponsor support.
The Mental Health TALK SAFE Act of 2026 (HR 6994) was introduced on January 9, 2026 by Representative Neal Dunn (R-FL-2) and referred to the House Committee on Energy and Commerce and the Committee on the Judiciary. The bill amends the Controlled Substances Act to allow telehealth practitioners to prescribe controlled substances for mental health conditions (Schedule II non-narcotics, III, IV, V) and opioid use disorder after a single telehealth evaluation, eliminating the current in-person examination requirement. The bill has one cosponsor and is in the earliest legislative stage.
This bill authorizes no direct funding — it is a regulatory reform that removes a statutory barrier. The mechanism is a change to the definition of 'valid prescription' under 21 U.S.C. 829(e)(2). No appropriations are involved. The financial impact is structural: if passed, it would permanently expand the total addressable market for telehealth platforms that serve mental health and addiction treatment, currently constrained by the Ryan Haight Act's in-person requirements. The DEA's 2023-2024 temporary flexibilities and proposed rulemaking already provide a regulatory tailwind; this bill would codify those flexibilities permanently.
Structural winners: $TDOC (Teladoc) and $AMWL (American Well) are the primary pure-play public telehealth platforms. Both companies' mental health service lines (Teladoc's BetterHelp, Amwell's behavioral health integration) would benefit from expanded prescribing authority. However, this bill is early-stage — it has not cleared either committee, and its path to passage is uncertain given the small sponsor coalition. No market reaction to this bill has been observable, as the existing regulatory tailwind (DEA rulemaking) already drives sector dynamics.
Real market data shows $TDOC at $5.71 (30-day +4.77%, 7-day -0.7%) and $AMWL at $6.16 (30-day +17.11%, 7-day +4.76%). These moves reflect the broader telehealth sector sentiment and existing DEA regulatory developments, not this specific bill. The price action on $AMWL has been stronger, but both remain well within their 52-week ranges.
The legislative timeline: committee hearings, markup, floor vote (House), then Senate introduction and committee process. Given the 2026 election year calendar, meaningful progress is unlikely before 2027 unless attached as a rider to must-pass legislation. Retail investors should monitor committee hearing schedules and DEA final rulemaking as more concrete catalysts.
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Expansion of telehealth prescribing authority for controlled mental health substances (Schedule II non-narcotics, III, IV, V) and opioid use disorder treatments, removing the in-person evaluation requirement for these categories under the Controlled Substances Act.
Who must act
Telehealth practitioners seeking to prescribe approved mental health controlled substances and schedule II-V drugs for opioid use disorder without a prior in-person visit.
What happens
Expands the addressable prescription volume for telehealth providers by including mental health conditions treatable with controlled substances (e.g., ADHD, anxiety, depression) and opioid use disorder treatments, which were previously restricted by the Ryan Haight Act's in-person requirement.
Stock impact
Teladoc's BetterHelp and primary care segments can expand prescribing capabilities for controlled mental health substances, increasing patient acquisition and visit volume. However, this bill is early-stage and unlikely to drive near-term revenue changes before passage.
What the bill does
Expansion of telehealth prescribing authority for controlled mental health substances and opioid use disorder treatments, removing the in-person evaluation requirement for these categories.
Who must act
Telehealth practitioners seeking to prescribe controlled substances for mental health and opioid use disorder via telemedicine platforms.
What happens
American Well's enterprise platform for health systems and insurers can offer expanded prescribing capabilities, potentially increasing contract value per client as platform utility grows for behavioral health integration.
Stock impact
American Well's provider platform enables health systems to deliver virtual mental health services. Expanded prescribing authority increases platform stickiness and could drive incremental adoption among health systems seeking to integrate behavioral telehealth. Bill is early-stage with no near-term revenue impact.
Matched on shared policy language across AI analyses, with ticker & timing weight
To amend title XVIII of the Social Security Act to remove in-person requirements under Medicare for mental health services furnished through telehealth and telecommunications technology.
Audio-Only Telehealth Access Act of 2025
College Students Continuation of Mental Health Care Act of 2025
Second Chance Mental Health Access Act of 2026
Executive orders & memoranda affecting the same sectors or companies
The President invokes Section 232 of the Trade Expansion Act to declare that imports of robotics, industrial machinery, and their components threaten national security, and directs the Secretary of Commerce and USTR to negotiate agreements with trading partners to adjust these imports, potentially leading to tariffs or quotas within 180 days.
This proclamation initiates negotiations to adjust imports of wind turbines and their components under Section 232, citing national security concerns including cybersecurity vulnerabilities, radar interference, and grid reliability. It does not immediately impose tariffs but sets the stage for potential trade restrictions, and notes that certain wind turbine components made of aluminum, steel, or copper are already subject to existing tariffs.
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →